Business context and reporting period
India Globalization Capital, Inc. (IGC; now identified in the request as IGC Pharma) filed this Form 10-Q for its fiscal first quarter ended June 30, 2018, with comparative results for the three months ended June 30, 2017. The company’s fiscal year ends March 31. Its business comprised legacy infrastructure trading and equipment rental, and cannabinoid-based alternative therapies. All reported quarterly revenue came from the legacy business; alternative therapies had not yet generated revenue.
Financial results and liquidity
| Metric | Quarter ended June 30, 2018 | Prior-year quarter |
|---|---|---|
| Revenue | $1.478 million | $52,926 |
| Cost of revenue | $1.436 million | $6,880 |
| Gross profit / margin | $41,942 / approximately 2.8% | $46,046 / approximately 87.0% |
| SG&A | $553,645 | $442,315 |
| Operating loss | $511,703 | $396,269 |
| Net loss | $512,296 | $432,460 |
| Loss per share, basic and diluted | $0.02 | $0.02 |
| Operating cash flow | $(534,785) | $(521,933) |
Revenue growth reflected increased infrastructure commodity trading after the company moved that activity to a lower-overhead operating model, plus equipment rental. Gross profit was slim despite the revenue increase. Net loss widened by about $80,000, which management attributed primarily to higher SG&A. SG&A included $37,381 of R&D expense; the filing attributes much of the SG&A increase to expenses related to prior-year stock awards.
Cash and cash equivalents were $1.021 million at June 30, down $637,637 from March 31. Working capital was $460,373. Management reported an approximately $325,000 non-GAAP cash burn after adjustment for noncash items. Operating cash use reflected the loss and a $1.431 million increase in accounts receivable, partly offset by higher trade payables. Investing cash use was $7,807; financing cash use was $67,327, mainly loan repayments. Total liabilities were $3.939 million, including $1.8 million of current notes payable and $226,375 of noncurrent loans. Stockholders’ equity was $7.577 million.
Material changes and notable items
- Accounts receivable rose to $1.988 million from $557,813 at March 31. The filing says $407,978 of aged receivables relate to Cochin International Airport; the company carries the full amount without impairment, citing a favorable arbitration ruling and low perceived collection risk.
- Inventory, consisting of work in process for Hyalolex, increased to $649,603 from $486,497. The filing says components may be sold or used for educational and marketing demonstrations.
- Foreign currency translation reduced comprehensive income by $306,464 in the quarter.
- The company reported 31,038,473 common shares outstanding at June 30 and approximately the same number as of July 27, 2018. Potential shares were excluded from diluted EPS as antidilutive.
- The company classified its Malaysian real estate subsidiary as held for sale at $147,500 and expected to sell it during fiscal 2019.
Outlook, risks, and contingencies
Management expected Hyalolex commercialization through medical dispensaries in the second half of calendar 2018, initially targeting 10 states, beginning with Puerto Rico, Maryland, the District of Columbia, and California. The filing provides no quantified sales or profit guidance for the therapy. Management said additional capital would be needed for FDA filings and preclinical and clinical trials, and cited a shelf registration and other potential financing or partnership options. For the legacy business, management’s stated strategy was to maintain annual revenue of $3 million to $5 million, improve margins, reduce financing costs, and make modest equipment investments.
Key risks include U.S. federal cannabis prohibition and enforcement uncertainty, possible FDA regulation and compliance costs, and whether products gain acceptance among medical professionals and patients. The company noted that it could face delays or lose access to its planned U.S. market. A dispute with Bricoleur Partners concerned a $1.8 million no-interest note and shares previously issued as penalties; IGC filed suit in May 2018 seeking a declaratory judgment and damages, and the case was pending. The filing otherwise stated that no significant contingencies or commitments existed and that there were no material legal proceedings against the company. Management reported disclosure controls were effective at a reasonable-assurance level and no material changes in internal control during the quarter.
Important facts for investors to verify
- Whether the sharp receivables increase, including the aged airport balance, converts to cash as expected.
- Whether legacy trading can sustain revenue while improving its reported roughly 2.8% gross margin.
- Hyalolex’s actual launch timing, legal market access, regulatory pathway, and ability to generate revenue; the filing reports no alternative-therapy sales for the quarter.
- Cash runway and the terms, timing, and dilution implications of capital needed for planned regulatory and clinical work.
- The status and potential financial or share-count consequences of the Bricoleur note dispute and related prior share issuances.
- Whether disclosed share counts and warrant terms remain current; the filing reports substantial potential dilution from outstanding warrants and options.